Search clinical trials for: Tacrolimus and Thymoglobulin

Total 269562 results

Barbara Ann Karmanos Cancer Institute

Completed

Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT

Hematological Malignancies

United States
Hadassah Medical Organization

Completed

Thymoglobuline in Non-myeloablative Allogeneic Stem-cell Transplantation

Stem Cell Transplantation | Graft Vs Host Disease

Israel
University Hospital, Basel, Switzerland

Completed

Comparison of ATG to Thymoglobuline in Renal Transplantation

Transplantation, Kidney

Switzerland
University of Nebraska
Genzyme, a Sanofi Company

Unknown

A Study of Thymoglobulin and Tacrolimus in Liver Transplant (thymo)

Liver Transplantation | Liver Disease | Immunosuppression

United States
The Cleveland Clinic
Genzyme, a Sanofi Company

Completed

Low Dose Thymoglobulin to Protect Kidney Function After Liver Transplant

Liver Transplantation

United States
University Hospital, Toulouse

Completed

Benefit of Immunoprophylaxis on Fibrosis to Reduce Viral Load After Liver Transplantation (BEFIRTH)

Liver Transplantation

France
National Taiwan University Hospital

Terminated

De Novo Everolimus-based Therapy for Renal Transplantation Using Rituximab Induction

Renal Insufficiency

Taiwan
European Institute of Oncology
Istituto Clinico Humanitas

Terminated

Allogenic Haematopoietic Cell Transplantation for Patients With Refractory "Triple Negative" Breast Cancer

Breast Cancer

Italy
Gang Chen
Changhai Hospital; First Affiliated Hospital, Sun Yat-Sen University; The First... and other collaborators

Completed

Pediatric Induction Therapy in Kidney Transplantation (PINK)

Kidney Transplant Rejection | Pediatric Kidney Disease

China
Helio Tedesco Silva Junior
Sanofi; Novartis

Completed

Comparison Between Two Tacrolimus-based Immunosuppressant Regimens and Induction With Thymoglobulin in Kidney Transplants From Deceased Donors With Expanded Criteria

Kidney Transplantation | Cytomegalovirus

Brazil
University of California, Los Angeles
Genzyme, a Sanofi Company

Withdrawn

Intraoperative Versus Postoperative Thymoglobulin in Lung Transplantation

Lung Transplant

United States
European Society for Blood and Marrow Transplantation
Genzyme, a Sanofi Company

Completed

Rabbit Antithymocyte Globulin (Thymoglobuline) With Ciclosporin for Patients With Acquired Aplastic Anaemia (RATGAA07)

Aplastic Anemia

Switzerland, United Kingdom, Germany, Italy, France, Saudi Arabia
Kasr El Aini Hospital

Completed

Efficiency of Fractional-Laser Resurfacing Followed by Topical Tacrolimus 0.03% Cream vs Tacrolimus Alone in Vitiligo

Stable Vitiligo
Chinese PLA General Hospital

Recruiting

Efficacy and Safety Study of 4-Day ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT

aGVHD | cGVHD

China
National Institute of Allergy and Infectious Diseases...

Completed

Antibody and Delayed Cyclosporine Versus Initial Cyclosporine Alone in Patients Receiving Kidney Transplants

Kidney Transplantation | Chronic Allograft Nephropathy

United States
King Faisal Specialist Hospital & Research Center

Completed

Prospective Phase II Study of Rabbit Antithymocyte Globulin (ATG, Thymoglobuline®, Genzyme) With Ciclosporin for Patients With Acquired Aplastic Anaemia

Acquired Aplastic Anaemia
National Institute of Allergy and Infectious Diseases...
Clinical Trials in Organ Transplantation

Terminated

Immune Monitoring and CNI Withdrawal in Low Risk Recipients of Kidney Transplantation

Kidney Transplant Recipients

United States, Canada
M.D. Anderson Cancer Center
Genzyme, a Sanofi Company

Terminated

Thymoglobulin (ATG) Dose Finding Study

Graft vs Host Disease

United States
Assiut University

Unknown

The Effect of Fractional Co2 Laser Either With Tacrolimus, Calcipotriol or NB-UVB in Stable Generalized Vitiligo

Vitiligo Vulgaris
Nantes University Hospital

Completed

Study of a Reduced-toxicity "Submyeloablative" Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies (ITT 08-01)

Hematological Malignancies

France
Institut Paoli-Calmettes
Sanofi

Not yet recruiting

PROPHYLAXIS OF GVH IN ELDERLY PATIENTS RECEIVING HAPLOIDENTICAL ALLOGENIC HEMATOPOIETIC STEM CELL TRASNPLANTATION USE OF A LOW DOSE ANTI-LYMPHOCYTIC SERUM (CASPER)

Hematological Malignancy
Washington University School of Medicine
Genzyme, a Sanofi Company

Completed

A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma

Relapsed Or Refractory Multiple Myeloma

United States
University Hospital, Lille
Erasme University Hospital

Completed

Daclizumab Versus Thymoglobulin in Renal Transplant Recipients With High Immunological Risk (TAXI)

Renal Transplantation

France
University of Cincinnati
Genzyme, a Sanofi Company

Completed

Prospective Pilot Study of Pre-Transplant Thymoglobulin Administration in Living Donor Renal Transplant Recipients

Renal Transplant Rejection | Transplants and Implants

United States
Ronaldo de Matos Esmeraldo, MD
Novartis Pharmaceuticals

Completed

Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant

Cytomegalovirus Infections | Transplantation Infection

Brazil
Peking University People's Hospital

Completed

Anti-thymocyte Globulins for Graft-versus-host Disease Prophylaxis

Leukemia, GVHD, ATG, Transplantation

China
University Hospital, Brest

Unknown

Influence of Thymoglobuline on Phenotypic and Functional Profiles of B Lymphocytes in Renal Transplant Recipients (THYMO B)

Renal Transplant

France
University Hospital Freiburg
Roche Pharma AG; Genzyme, a Sanofi Company; Astellas Pharma GmbH

Completed

Phase IV Study to Evaluate Calcineurin Inhibitor Reduced, Steroid Free Immunosuppression After Renal Transplantation (Harmony)

Disorder Related to Renal Transplantation

Germany
Hospices Civils de Lyon

Recruiting

Thymoglobulin® Pharmacokinetics in Patients Undergoing Hematopoietic Stem Cell Transplantation (PHASAL-GA)

Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy

France
Astellas Pharma Inc

Completed

Phase III Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis

Keratoconjunctivitis | Conjunctivitis

Japan
University Hospital Tuebingen

Terminated

Haploidentical Stem Cell Transplantation With CD3/CD19 Depletion and Reduced Intensity Conditioning in Patients With Acute Leukemia (CD3/CD19 Haplo)

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia

Germany
Institut Paoli-Calmettes
Agence de La Biomédecine

Completed

Study Evaluating the Efficacy of Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous (Busilvex®) in Patients at High Risk of Carrying Blood Diseases (BX-PK)

Hematological Diseases

France
Novartis Pharmaceuticals

Completed

Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients

Liver Transplant Recipient

Belgium, Spain, Germany, Italy, Australia, United States, Netherlands, Ireland, Sweden, Brazil, Colombia, France, Russian Federation, Argentina, Czechia, United Kingdom
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients (RAD)

Liver Transplantation

United States, Belgium, Colombia, Spain, Germany, Italy, Australia, Israel, France, Hungary, Netherlands, Argentina, Canada, Ireland, Sweden, Brazil, United Kingdom, Russian Federation, Czech Republic
Shanghai General Hospital, Shanghai Jiao Tong University...

Unknown

ATG Based Conditioning Regimen in HLA Related HSCT for Aggressive T-cell Tumors

Lymphoblastic Lymphoma

China
The Hospital for Sick Children

Terminated

Pharmacokinetics of Thymoglobulin in Paediatric Haematopoietic Stem-cell Transplants

Metabolic Disease | Genetic Disorder | Malignancy

Canada
Nantes University Hospital

Completed

Study of a Reduced-toxicity Myeloablative Conditioning Regimen Using Fludarabine and Full Doses of Intravenous Busulfan in Pediatric Patients Not Eligible for Standard Myeloablative Conditioning Regimens (FB4-PEDIA)

Hematologic Malignancy

France
Astellas Pharma Inc
Astellas Pharma Korea, Inc.

Completed

Pharmacokinetics of Tacrolimus in Liver Transplantation Patients Treated With Prograf and Modified Release Tacrolimus

Liver Transplantation

Korea, Republic of
Heleen Grootjans
Chiesi Farmaceutici S.p.A.

Recruiting

Trial Comparing Immediate Versus Extended Release Tacrolimus; Reducing Calcineurin Inhibitor Related Toxicity in Lung Transplantation Patients (REVOLUTION)

Lung Transplant; Complications

Netherlands
Lahey Clinic
Brigham and Women's Hospital

Completed

Low Dose Thymoglobin in Renal Transplant Patients

Acute Renal Failure

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI); National Institutes of Health (NIH)

Terminated

Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation

Graft Versus Host Disease

United States
Enzyvant Therapeutics GmBH

Approved for marketing

Expanded Access Protocol Thymus Transplantation

Immunodeficiency | Poor Thymic Function | Athymia | Immunoreconstitution | Thymus Transplantation | Low T Cell Numbers
Genzyme, a Sanofi Company

Completed

An Open-label, Prospective, Randomized, Multi-center, Phase II Comparative Trial of Thymoglobulin Versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients.

Cadaveric Donor Renal Transplantation | Acute Renal Allograft Rejection | Induction Therapy

United States, France, Spain, United Kingdom, Germany
Genzyme, a Sanofi Company

Completed

A Study to Evaluate the Effect of Thymoglobulin and Reduced Doses of Steroids to Prevent Renal Transplant Rejection

Graft Rejection | Renal Transplantation

United States
Limerick BioPharma

Completed

Safety and Tolerability of LIM-0705 in Healthy Male Subjects (LIM)

Healthy

Australia
King's College Hospital NHS Trust

Terminated

Pilot Study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients With Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) Utilising Conditioning With Fludarabine, Busulphan and Thymoglobulin (FB-ATG)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United Kingdom
The Methodist Hospital Research Institute
Veloxis Pharmaceuticals

Withdrawn

Evaluation of Anti-rejection Drug, Tacrolimus, in African-Americans With Kidney Transplant

Acute Rejection of Renal Transplant | Kidney Disease, End-Stage | Donor Specific Antibodies
University of Oxford
Genzyme, a Sanofi Company; Oxford University Hospitals NHS Trust

Unknown

Thymoglobulin Induction in Kidney Transplant Recipients (TIKT)

Kidney Transplantation | Ischemia-Reperfusion Injury

United Kingdom
Peking Union Medical College Hospital

Unknown

Tacrolimus Treatment for Refractory PRCA

Pure Red Cell Aplasia

China
Taro Pharmaceuticals USA

Completed

Bioequivalence of Two Tacrolimus 0.1% Topical Ointment Formulations in Patients With Atopic Dermatitis

Atopic Dermatitis

Search clinical trials for: Tacrolimus and Thymoglobulin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations